Nuvation Bio Q1 2026 net product revenue $18.5M; net income $5.4M vs loss year ago

Nuvation Bio Inc.

2026-Q1 EPS reported $0.01 revenue$83,228,000

Net product revenue $18.5M from IBTROZI; net income $5.4M ($0.02 basic EPS) vs net loss $53.2M year ago.
Collaboration revenue $64.7M including $58.7M upfront from Eisai; cash and securities $533.7M.
Over 600 patients started IBTROZI since launch; majority of ~200 new Q1 patients were TKI-naïve.
Acquired Japan rights to safusidenib from Daiichi Sankyo, gaining full global development and commercialization rights.
Updated pooled TRUST data at AACR: mPFS 46.1 months, mDOR 49.7 months in TKI-naïve ROS1+ NSCLC.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Nuvation Bio Inc. reported first quarter ended March 31, 2026 results: revenue $18.5 million.

Period: first quarter ended March 31, 2026
Revenue: $18.5 million
Result: reported results

Exact text from the filing

Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update Achieved $18.5 million in first quarter of 2026 net product revenues for IBTROZI

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Nuvation Bio Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-204056

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.